EyePoint Pharmaceuticals, Inc

(NASDAQ:EYPT)

Latest On EyePoint Pharmaceuticals, Inc (EYPT):

Date/Time Type Description Signal Details
2023-05-30 14:28 ESTNewsEyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug SuccessN/A
2023-05-18 19:57 ESTNewsAlimera jumps 48% on deal with EyePoint for eye disorder therapy YutiqN/A
2023-05-04 11:48 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call TranscriptN/A
2023-05-03 23:29 ESTNewsEyePoint stock soars 20% after Q1 sees growth in Yutiq salesN/A
2023-05-03 10:09 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 beats by $0.13, revenue of $7.68M beats by $0.11MN/A
2023-05-02 22:14 ESTNewsEyePoint Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-02 16:14 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$1.16 misses by $0.54, revenue of $10.53M beats by $0.13MN/A
2023-03-02 16:13 ESTNewsEyePoint stock dips as Q4 net loss widens, revenue fallsN/A
2023-03-02 16:13 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 01:38 ESTNewsEyePoint Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-27 14:25 ESTNewsRallybio, EyePoint in collaboration for geographic atrophy therapyN/A
2023-01-23 14:54 ESTNewsEyePoint inks lease for setting up of new manufacturing facility in MassachusettsN/A
2023-01-04 19:07 ESTNewsEyePoint Pharmaceuticals promotes Jay S. Duker to PresidentN/A
2022-11-02 16:59 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.49 beats by $0.16, revenue of $10.01M misses by $0.91MN/A
2022-11-02 16:58 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call TranscriptN/A
2022-08-30 20:33 ESTNewsEyePoint Pharma stock tumbles 14% postmarket on subpoena related to Dexycu salesN/A
2022-08-30 04:14 ESTNewsEyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD SpaceN/A
2022-08-03 20:25 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74MN/A
2022-08-03 20:24 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call TranscriptN/A
2022-07-19 02:49 ESTNewsEyePoint reports preliminary Q2 net product revenue $11.3MN/A
2022-07-15 12:59 ESTNewsEyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMDN/A
2022-06-22 02:08 ESTNewsEyePoint, OcuMension's eye implant therapy implant Yutiq gets approval in ChinaN/A
2022-05-05 03:05 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 in-line, revenue of $9.3M misses by $0.59MN/A
2022-05-05 03:05 ESTNewsEyePoint Q1 net loss widens Y/Y; inks license deal with China's Betta for EYP-1901N/A
2022-05-05 03:04 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call TranscriptN/A
2022-05-03 13:09 ESTNewsEyePoint Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-09 23:17 ESTNewsEyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley BankN/A
2022-03-04 04:42 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-03 11:12 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75MN/A
2022-03-02 16:55 ESTNewsEyePoint Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-14 07:42 ESTNewsEyePoint Pharmaceuticals reports positive data EYP-1901 data for the treatment of wet AMDN/A
2021-12-08 06:00 ESTNewsEyePoint, ImprimisRx expand commercial alliance for Dexycu eye corticosteroidN/A
2021-11-20 08:20 ESTNewsEyepoint Pharmaceuticals (EYPT) Investor Presentation - SlideshowN/A
2021-11-17 17:02 ESTNewsEyePoint Pharma secures $100M capital raise via equity offeringN/A
2021-11-17 17:01 ESTNewsShares of EyePoint Pharma soar 27% after pricing $100M equity offeringN/A
2021-11-16 20:09 ESTNewsEyePoint Pharma slumps on offering of $100M common sharesN/A
2021-11-15 05:04 ESTNewsEyePoint Pharma reports positive EYP-1901 data for treatment of wet AMDN/A
2021-11-04 08:34 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 11:51 ESTNewsEyePoint Pharmaceuticals EPS misses by $0.18, misses on revenueN/A
2021-11-02 15:45 ESTNewsEyePoint Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-13 00:22 ESTNewsEyePoint says its wet AMD therapy posed no serious adverse events in early studyN/A
2021-08-05 04:20 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.09, beats on revenueN/A
2021-08-05 04:17 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 07:32 ESTNewsEyePoint Pharmaceuticals to join Russell 2000 and 3000 IndexN/A
2021-07-21 07:24 ESTNewsEyePoint Pharma reports positive EYP-1901 results in wet-AMDN/A
2021-05-05 15:43 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.01, misses on revenueN/A
2021-05-05 15:39 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-23 12:43 ESTNewsEyePoint Pharmaceuticals End Of Year Earnings Call AnalysisN/A
2021-03-06 07:38 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 07:43 ESTEarnings EstimateAn EPS average of -$0.89 is estimated for the 2022 year.Buy

About EyePoint Pharmaceuticals, Inc (EYPT):

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Quotes by TradingView

See Advanced Chart

General

  • Name EyePoint Pharmaceuticals, Inc
  • Symbol EYPT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:10
  • Last Split Date2020-12-09
  • Fiscal Year EndDecember
  • IPO Date2005-01-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://eyepointpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.93
  • Price/Book (Most Recent Quarter) 16.32
  • Enterprise Value Revenue 8.65
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.71
  • Next Year EPS Estimate -$1.43
  • Next Quarter EPS Estimate -$0.62
  • Profit Margin -132%
  • Operating Margin -107%
  • Return on Assets -28%
  • Return on Equity -338%
  • Revenue 34.44 million
  • Earnings Per Share -$0.72
  • Revenue Per Share $2.68
  • Gross Profit 11.19 million
  • Quarterly Earnings Growth -17.4%
View More

Highlights

  • Market Capitalization 317.88 million
  • EBITDA -56213000
  • Analyst Target Price $19.25
  • Book Value Per Share $1.02
View More

Share Statistics

  • Shares Outstanding 28.74 million
  • Shares Float 19.88 million
  • % Held by Insiders 73%
  • % Held by Institutions 46.62%
  • Shares Short 381742
  • Shares Short Prior Month 350229
  • Short Ratio 0.8
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.33
  • 52 Week High $15.06
  • 52 Week Low $3.51
  • 50 Day Moving Average 12.02
  • 200 Day Moving Average 7.3
View More

Dividends

  • Dividend Date 2020-12-09
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

EyePoint Pharmaceuticals, Inc (EYPT) Dividend Calendar:

EYPT's last dividend payment was made to shareholders on December 9, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

EyePoint Pharmaceuticals, Inc (EYPT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$7.13 million-$1.07-$0.17-536.9%
2020-09-302020-11-05$N/A-$0.30-$0.3718.19%
2020-06-302020-08-05$N/A-$1.00-$1.109.09%
2020-03-312020-05-06$7.49 million-$1.10-$0.97-13.79%
2019-12-312020-03-05$8.63 million-$1.00-$1.1513.04%
2019-09-302019-11-07$2.51 million-$1.50-$1.25-20%
2019-06-302019-08-07$7.21 million-$1.10-$1.4021.43%
2019-03-312019-05-08$2.01 million-$2.00-$0.90-122.22%
2018-12-312019-03-14$2.44 million-$1.20-$1.4014.29%
2018-09-302018-11-06$486000-$0.44-$0.15-193.33%
2018-06-302018-09-12$715000-$6.20-$1.07-481.23%
2018-03-312018-05-08$928000-$1.50-$1.30-15.38%
2017-12-312018-02-07$933000-$1.30-$1.5013.33%
2017-09-302017-11-07$385000-$1.50-$1.500%
2017-06-302017-09-11$701000-$1.60-$1.50-6.67%
2017-03-312017-05-04$590000-$1.50-$1.500%
2016-12-312017-02-07$5.97 million$-0.00-$1.8399.89%
2016-09-302016-11-07$277000-$2.10-$1.90-10.53%
2016-06-302016-09-12$304000-$1.90-$1.25-52%
2016-03-312016-05-05$324000-$1.50-$1.9523.08%
2015-12-312016-02-08$526000-$1.80-$1.50-20%
2015-09-302015-11-05$466000-$0.17-$0.14-21.43%
2015-06-302015-09-09$409000-$0.17-$0.13-30.77%
2015-03-312015-05-08$328000-$0.17-$0.13-30.77%
2014-12-312015-02-05$521000-$0.14-$0.13-7.69%
2014-09-302014-11-07$25.31 million$0.67-$0.12658.33%
2014-06-302014-09-09$292000-$0.14-$0.140%
2014-03-312014-05-13$1.99 million-$0.08-$0.1546.67%
2013-12-312014-02-07$592000-$0.13-$0.130%
2013-09-302013-11-12$597000-$0.14-$0.13-7.69%
2013-06-302013-09-25$492000-$0.17-$0.12-41.67%
2013-03-312013-05-13$513000-$0.12-$0.137.69%
2012-12-312013-02-06$585000-$0.11-$0.1315.38%
2012-09-302012-11-08$553000-$0.11-$0.10-10%
2012-06-302012-09-24$699000-$0.11-$0.1942.11%
2012-03-312012-05-09$538000-$0.13-$0.1723.53%
2011-12-312012-02-08$630000-$0.13-$0.1723.53%
2011-09-302011-11-07$1.66 million-$0.12-$0.2142.86%
2011-06-302011-09-12$3.72 million-$0.01-$0.1894.44%
2011-03-312011-05-10$360000-$0.13-$0.2138.1%
2010-12-312011-02-09$414000-$0.15$0.45-133.33%
2010-09-302010-11-05$476000-$0.17-$0.14-21.43%
2010-06-302010-09-23$15.72 million$6.80
2010-03-312010-05-12$515000-$0.15-$0.1922.95%
2009-12-312010-02-12$3.43 million-$0.01
2009-09-302009-11-13$3.38 million-$0.87
2009-06-302009-09-25$3.22 million-$0.29
2009-03-312009-05-13$3.16 million-$0.35
2008-12-312009-02-11$2.97 million-$0.48
2008-09-302008-11-11$2.81 million-$0.26
2008-06-302008-06-30$2.7 million-$35.00
2008-03-312008-03-31$542000-$12.05
2007-12-312007-12-31$128000-$12.70
2007-09-302007-09-30$103000-$1.78

EyePoint Pharmaceuticals, Inc (EYPT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 5.21 million N/A N/A 4.85 million N/A
Income Before Tax -15.47 million N/A N/A -13.17 million -10.41 million
Selling General Administrative 11.59 million N/A N/A 12.49 million 11.55 million
Gross Profit 4.67 million N/A N/A 6.51 million 3.18 million
Ebit -13.03 million N/A N/A -10.78 million -8.99 million
Operating Income -12.74 million N/A N/A -11.44 million -8.99 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 7.13 million N/A N/A 7.49 million 8.63 million
Cost of Revenue 2.46 million N/A N/A 980000 5.46 million
Total Other Income Expense Net -905000 N/A N/A N/A -1.42 million
Net Income From Continuing Operations -15.47 million N/A N/A -13.17 million -10.41 million
Net Income Applicable to Common Shares N/A -3.8 million -12.95 million -13.17 million -10.41 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 2.93 million -428000 N/A N/A N/A
Total Cash Flow from Investing Activities -128000 -26000 N/A N/A N/A
Net Borrowings N/A 2.03 million N/A N/A N/A
Total Cash Flow from Financial Activities 4.9 million N/A N/A N/A N/A
Change to Operating Activities N/A -27000 N/A N/A N/A
Change in Cash 5.91 million N/A N/A N/A N/A
Total Cash from Operating Activities 1.14 million -5.12 million N/A N/A N/A
Depreciation 662000 N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory 132000 N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities 2.03 million N/A N/A N/A N/A
Change to Net Income 2.72 million 1.06 million N/A N/A N/A
Capital Expenditures 128000 N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 73.18 million N/A N/A 63.82 million 64.99 million
Total Stockholder Equity 18.54 million N/A N/A 16.47 million 8.33 million
Other Current Liabilities 687000 897000 N/A 551000 15000
Total Assets 91.72 million N/A N/A 80.29 million 73.32 million
Common Stock N/A 501.97 million 125000 494.09 million 472.78 million
Other Current Assets N/A N/A N/A N/A 8.14 million
Retained Earnings -510.68 million -495.21 million -491.41 million -478.46 million -465.29 million
Other Liabilities N/A 3.01 million 3.03 million 3.04 million 3 million
Other Assets N/A 642000 150000 575000 507000
Cash 44.91 million N/A N/A 26.3 million 22.21 million
Total Current Liabilities 14.89 million 12.93 million N/A 10.3 million 11.87 million
Other Stockholder Equity N/A 840000 840000 840000 840000
Property, Plant & Equipment N/A 2.73 million 3.26 million 2.97 million 3.08 million
Total Current Assets 63.12 million 47.59 million N/A 49.69 million 42.07 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets N/A -18.23 million -22.25 million -10.58 million -19.34 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 37.98 million N/A N/A 47.72 million 47.22 million
Inventory 5.34 million 3.64 million N/A 3.36 million N/A
Accounts Payable 4.81 million 12.03 million N/A N/A 11.38 million

EyePoint Pharmaceuticals, Inc (EYPT) Chart:

EyePoint Pharmaceuticals, Inc (EYPT) News:

Below you will find a list of latest news for EyePoint Pharmaceuticals, Inc (EYPT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

EyePoint Pharmaceuticals, Inc (EYPT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-182.50CALL0 0283.32TRUE00
2026-06-1850CALL0 0189.75TRUE00
2026-06-187.50CALL0 0139.63TRUE00
2026-06-18104.6CALL0 12108.59TRUE00
2026-06-1812.51.77CALL11 3484.81TRUE1.770
2026-06-18150.6CALL170 10873.54FALSE-0.02-0.03
2026-06-1817.50CALL0 199.74FALSE00
2026-06-18200.2CALL0 9116.78FALSE00
2026-06-1822.50CALL0 0137.46FALSE00
2026-06-18250CALL0 0154.97FALSE00
2026-06-182.50PUT0 0447.03FALSE00
2026-06-1850PUT0 0268.2FALSE00
2026-06-187.50PUT0 0172.05FALSE00
2026-06-18100PUT0 0116.01FALSE00
2026-06-1812.50.74PUT5 8168.52FALSE-0.01-0.01
2026-06-18150PUT0 160.42TRUE00
2026-06-1817.50PUT0 00TRUE00
2026-06-18200PUT0 00TRUE00
2026-06-1822.50PUT0 00TRUE00
2026-06-18250PUT0 00TRUE00
2026-07-172.50CALL0 0234.88TRUE00
2026-07-1750CALL0 90199.38TRUE00
2026-07-177.50CALL0 156107.74TRUE00
2026-07-17100CALL0 147110.02TRUE00
2026-07-1712.52.73CALL0 110100.62TRUE00
2026-07-17151.3CALL2 7186.68FALSE-0.12-0.08
2026-07-1717.50CALL0 14084.57FALSE00
2026-07-17200CALL0 68097.49FALSE00
2026-07-1722.50CALL0 109106.79FALSE00
2026-07-17250CALL0 205121.9FALSE00
2026-07-17300CALL0 2217143.69FALSE00
2026-07-17350CALL0 10161.06FALSE00
2026-07-172.50PUT0 0357.67FALSE00
2026-07-1750PUT0 1214.21FALSE00
2026-07-177.50PUT0 0138.36FALSE00
2026-07-17100PUT0 5896.85FALSE00
2026-07-1712.50PUT0 21985.68FALSE00
2026-07-17150PUT0 2798.06TRUE00
2026-07-1717.50PUT0 1892.78TRUE00
2026-07-17200PUT0 13782.55TRUE00
2026-07-1722.50PUT0 50TRUE00
2026-07-17250PUT0 120TRUE00
2026-07-17300PUT0 00TRUE00
2026-07-17350PUT0 00TRUE00
2026-08-212.50CALL0 0257.94TRUE00
2026-08-2150CALL0 1214.9TRUE00
2026-08-217.50CALL0 0196.17TRUE00
2026-08-21106.4CALL0 4211.09TRUE00
2026-08-2112.50CALL0 34173.16TRUE00
2026-08-21154.17CALL0 25176.29FALSE00
2026-08-2117.53.67CALL0 29172.53FALSE00
2026-08-21200CALL0 4173.71FALSE00
2026-08-2122.50CALL0 120170.6FALSE00
2026-08-21251.85CALL0 79167.45FALSE00
2026-08-21301.3CALL0 2168.06FALSE00
2026-08-21350.9CALL0 4168.72FALSE00
2026-08-212.50PUT0 0288.17FALSE00
2026-08-2150PUT0 2200.66FALSE00
2026-08-217.50PUT0 13187.12FALSE00
2026-08-21100PUT0 3015165.6FALSE00
2026-08-2112.53.7PUT0 17185.86FALSE00
2026-08-21150PUT0 7182.89TRUE00
2026-08-2117.50PUT0 0169.36TRUE00
2026-08-21200PUT0 228168.43TRUE00
2026-08-2122.50PUT0 16156.47TRUE00
2026-08-21250PUT0 0158.13TRUE00
2026-08-21300PUT0 0154.39TRUE00
2026-08-21350PUT0 0151.35TRUE00
2026-10-162.50CALL0 0255TRUE00
2026-10-1650CALL0 0221.9TRUE00
2026-10-167.50CALL0 0200.17TRUE00
2026-10-16100CALL0 2196.86TRUE00
2026-10-1612.50CALL0 13216.14TRUE00
2026-10-16150CALL0 12208.48FALSE00
2026-10-1617.55CALL0 3968203.89FALSE00
2026-10-16200CALL0 31191.42FALSE00
2026-10-1622.50CALL0 30168.54FALSE00
2026-10-16254.5CALL0 3705174.42FALSE00
2026-10-16300CALL0 41204.16FALSE00
2026-10-16353.1CALL0 21211.54FALSE00
2026-10-162.50PUT0 0271.04FALSE00
2026-10-1650PUT0 7222.9FALSE00
2026-10-167.50PUT0 20218.82FALSE00
2026-10-16104PUT0 10034196.01FALSE00
2026-10-1612.55.4PUT0 26226.25FALSE00
2026-10-16150PUT0 3539209.83TRUE00
2026-10-1617.50PUT0 193206.07TRUE00
2026-10-16200PUT0 0183.69TRUE00
2026-10-1622.50PUT0 4180.09TRUE00
2026-10-16250PUT0 0182.23TRUE00
2026-10-16300PUT0 2198.77TRUE00
2026-10-16350PUT0 0192.72TRUE00
2026-12-182.50CALL0 3206.97TRUE00
2026-12-1850CALL0 64196.04TRUE00
2026-12-187.50CALL0 151183.83TRUE00
2026-12-18108CALL0 169189.21TRUE00
2026-12-1812.50CALL0 68191.51TRUE00
2026-12-18150CALL0 2155165.01FALSE00
2026-12-1817.55.73CALL0 615169.96FALSE00
2026-12-18200CALL0 53165.99FALSE00
2026-12-1822.50CALL0 98164.55FALSE00
2026-12-18254.2CALL0 75161.92FALSE00
2026-12-18300CALL0 10163.08FALSE00
2026-12-18353.19CALL0 1096162.56FALSE00
2026-12-182.50PUT0 0226.12FALSE00
2026-12-1850PUT0 1225.9FALSE00
2026-12-187.50PUT0 5185.68FALSE00
2026-12-18100PUT0 102177.43FALSE00
2026-12-1812.50PUT0 403177.61FALSE00
2026-12-18150PUT0 0180.13TRUE00
2026-12-1817.50PUT0 0178.42TRUE00
2026-12-18200PUT0 0175.01TRUE00
2026-12-1822.50PUT0 0161.53TRUE00
2026-12-18250PUT0 1158.51TRUE00
2026-12-18300PUT0 0148.15TRUE00
2026-12-18350PUT0 0160.68TRUE00
2027-01-152.50CALL0 0200.73TRUE00
2027-01-1550CALL0 1184.15TRUE00
2027-01-157.50CALL0 0177.07TRUE00
2027-01-15100CALL0 1170.72TRUE00
2027-01-1512.50CALL0 3176.86TRUE00
2027-01-15150CALL0 3157.78FALSE00
2027-01-1517.50CALL0 0163.62FALSE00
2027-01-15200CALL0 2154.81FALSE00
2027-01-1522.50CALL0 0163.03FALSE00
2027-01-15250CALL0 0162.75FALSE00
2027-01-15300CALL0 0155.05FALSE00
2027-01-15350CALL0 3159.79FALSE00
2027-01-152.50PUT0 0228.82FALSE00
2027-01-1550PUT0 1254.33FALSE00
2027-01-157.50PUT0 0196.43FALSE00
2027-01-15100PUT0 2171.05FALSE00
2027-01-1512.50PUT0 10180.18FALSE00
2027-01-15157.2PUT0 1161.98TRUE00
2027-01-1517.50PUT0 0164.83TRUE00
2027-01-15200PUT0 0153.32TRUE00
2027-01-1522.50PUT0 0152.94TRUE00
2027-01-15250PUT0 0151.34TRUE00
2027-01-15300PUT0 0155.75TRUE00
2027-01-15350PUT0 0146.56TRUE00
2028-01-212.50CALL0 0130.73TRUE00
2028-01-2150CALL0 0125.22TRUE00
2028-01-217.50CALL0 0123.4TRUE00
2028-01-21100CALL0 0115.56TRUE00
2028-01-2112.57.6CALL5 0115.45TRUE7.60
2028-01-21156.75CALL2 5109.81FALSE6.750
2028-01-2117.50CALL0 0113.92FALSE00
2028-01-21200CALL0 0108.4FALSE00
2028-01-2122.50CALL0 0110.37FALSE00
2028-01-21254.75CALL2 5103.97FALSE4.750
2028-01-212.50PUT0 00FALSE00
2028-01-2150PUT0 0158.42FALSE00
2028-01-217.50PUT0 0125.38FALSE00
2028-01-21100PUT0 0117.05FALSE00
2028-01-2112.50PUT0 0110.93FALSE00
2028-01-21157.9PUT5 0112.2TRUE7.90
2028-01-2117.50PUT0 0110.97TRUE00
2028-01-21200PUT0 0111.17TRUE00
2028-01-2122.50PUT0 0110.43TRUE00
2028-01-21250PUT0 0109.03TRUE00

Latest EYPT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST10$7.555
Jun 13, 2022 7:59 PM EST4$7.555
Jun 13, 2022 7:59 PM EST32$7.555
Jun 13, 2022 7:59 PM EST5$7.53
Jun 13, 2022 7:59 PM EST100$7.53

EyePoint Pharmaceuticals, Inc (EYPT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2018-11-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314102/000000000018036896/0000000000-18-036896-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm
2019-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924319003415/0000899243-19-003415-index.htm
2018-10-31S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518314121/0001193125-18-314121-index.htm
2018-11-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518315426/0001193125-18-315426-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312518318982/0001193125-18-318982-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312518323795/0001193125-18-323795-index.htm
2018-11-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518336713/0001193125-18-336713-index.htm
2018-12-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518345921/0001193125-18-345921-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519002516/0001193125-19-002516-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519008307/0001193125-19-008307-index.htm
2019-01-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519012973/0001193125-19-012973-index.htm
2019-01-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519012979/0001193125-19-012979-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519020750/0001193125-19-020750-index.htm
2019-02-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1314102/000119312519037699/0001193125-19-037699-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519044197/0001193125-19-044197-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519073987/0001193125-19-073987-index.htm
2019-03-1810-KTTransition reports [Rule 13a-10 or 15d-10]https://www.sec.gov/Archives/edgar/data/1314102/000119312519078454/0001193125-19-078454-index.htm
2019-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519088540/0001193125-19-088540-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519092951/0001193125-19-092951-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519094684/0001193125-19-094684-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519121055/0001193125-19-121055-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125776/0001193125-19-125776-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125782/0001193125-19-125782-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519140432/0001193125-19-140432-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519144237/0001193125-19-144237-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519153328/0001193125-19-153328-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/0001193125-19-185970-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519192395/0001193125-19-192395-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519195624/0001193125-19-195624-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519214582/0001193125-19-214582-index.htm
2019-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519216909/0001193125-19-216909-index.htm
2020-02-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520043553/0001193125-20-043553-index.htm
2020-02-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520046322/0001193125-20-046322-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520210092/0001193125-20-210092-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312520217649/0001193125-20-217649-index.htm
2020-11-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312520287418/0001193125-20-287418-index.htm
2019-01-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000562/0001562180-19-000562-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000563/0001562180-19-000563-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002006/0001562180-19-002006-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002007/0001562180-19-002007-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2019-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2019-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2019-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003506/0001562180-19-003506-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003509/0001562180-19-003509-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003660/0001562180-19-003660-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003661/0001562180-19-003661-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003662/0001562180-19-003662-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003663/0001562180-19-003663-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003664/0001562180-19-003664-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003665/0001562180-19-003665-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003666/0001562180-19-003666-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003667/0001562180-19-003667-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003668/0001562180-19-003668-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003669/0001562180-19-003669-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003958/0001562180-19-003958-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003959/0001562180-19-003959-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005159/0001562180-19-005159-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005160/0001562180-19-005160-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005547/0001562180-19-005547-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002036/0001562180-20-002036-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002042/0001562180-20-002042-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002043/0001562180-20-002043-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002044/0001562180-20-002044-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002045/0001562180-20-002045-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002046/0001562180-20-002046-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002047/0001562180-20-002047-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002048/0001562180-20-002048-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002049/0001562180-20-002049-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002050/0001562180-20-002050-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002051/0001562180-20-002051-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002054/0001562180-20-002054-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2020-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019029987/0001564590-19-029987-index.htm
2019-08-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019032836/0001564590-19-032836-index.htm
2019-09-098-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019034357/0001564590-19-034357-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019041352/0001564590-19-041352-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019041819/0001564590-19-041819-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019043812/0001564590-19-043812-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044172/0001564590-19-044172-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044762/0001564590-19-044762-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020000993/0001564590-20-000993-index.htm
2020-01-168-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001223/0001564590-20-001223-index.htm
2020-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001745/0001564590-20-001745-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020003097/0001564590-20-003097-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020005550/0001564590-20-005550-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020006023/0001564590-20-006023-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020008797/0001564590-20-008797-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314102/000156459020010956/0001564590-20-010956-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020015451/0001564590-20-015451-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020017306/0001564590-20-017306-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019026/0001564590-20-019026-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019028/0001564590-20-019028-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019253/0001564590-20-019253-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020021535/0001564590-20-021535-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020023640/0001564590-20-023640-index.htm
2020-06-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020028332/0001564590-20-028332-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020029661/0001564590-20-029661-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020030273/0001564590-20-030273-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020032264/0001564590-20-032264-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036425/0001564590-20-036425-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020036429/0001564590-20-036429-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036461/0001564590-20-036461-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020037729/0001564590-20-037729-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020040715/0001564590-20-040715-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020043596/0001564590-20-043596-index.htm
2020-10-06PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045941/0001564590-20-045941-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045966/0001564590-20-045966-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046049/0001564590-20-046049-index.htm
2020-10-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046585/0001564590-20-046585-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046623/0001564590-20-046623-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046655/0001564590-20-046655-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020050850/0001564590-20-050850-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020051654/0001564590-20-051654-index.htm
2018-11-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518002780/9999999995-18-002780-index.htm
2018-12-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518003103/9999999995-18-003103-index.htm

EyePoint Pharmaceuticals, Inc (EYPT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyePoint Pharmaceuticals, Inc (EYPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 73%
Institutional Ownership: 4662%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-15George ElstonChief Financial OfficerBuy10,000.001.4314,290.0010,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-06-30Dario A. PaggiarinoChief Medical OfficerBuy41,050.00101,193.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2018-11-15MICHAEL W ROGERSDirectorBuy100,000.001.13113,000.00112,500.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2019-06-21MICHAEL W ROGERSDirectorBuy6,667.00119,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-03-29David J MazzoDirectorBuy20,000.001.7735,400.00158,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-06-21David J MazzoDirectorBuy8,333.00166,333.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-09-06David J MazzoDirectorBuy417.00166,750.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-04-01Jay S. DukerDirectorBuy5,000.001.899,450.0017,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2020-03-12George ElstonChief Financial OfficerBuy10,000.000.969,600.0020,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2019-10-09David J MazzoDirectorBuy33,333.001.9564,999.35200,083.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-03-29Nancy LurkerPresident & CEOBuy28,500.001.7650,245.50240,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-06-14Nancy LurkerPresident & CEOBuy45,000.00285,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-03-29Douglas Evan GodshallDirectorBuy17,000.001.7529,784.0029,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2020-08-24George ElstonChief Financial OfficerBuy10,000.000.616,112.0030,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2019-06-27Nancy LurkerPresident & CEOBuy40,000.00325,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-21Douglas Evan GodshallDirectorBuy6,667.0036,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-04-12Jay S. DukerDirectorBuy20,000.001.7735,400.0037,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2020-09-04George ElstonChief Financial OfficerBuy10,000.000.484,800.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-05-13John B. LandisDirectorBuy40,000.001.7469,600.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2020-06-30David Scott JonesSVP & Chief Commercial OfficerBuy41,050.0041,050.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2019-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0042,612.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-21Jay S. DukerDirectorBuy6,667.0044,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2020-02-21Nancy LurkerPresident & CEOBuy137,174.00476,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2019-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0048,437.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2020-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0057,247.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-03-10Nancy LurkerPresident & CEOBuy98,000.001.06104,027.00574,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-06-14Nancy LurkerPresident & CEOBuy45,000.00619,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0063,079.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-06-27Nancy LurkerPresident & CEOBuy40,000.00659,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2019-06-21Kristine PetersonDirectorBuy6,667.006,667.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2020-06-30Nancy LurkerPresident & CEOBuy124,667.00784,467.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2019-04-01Leonard S RossOfficerBuy5,000.001.819,050.0079,452.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-06-14Leonard S RossOfficerBuy8,280.0087,732.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-27Leonard S RossOfficerBuy6,667.0092,005.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2018-12-22Leonard S RossOfficerBuy62,892.0094,709.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm